Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986059 | 0.92 | TRPV1 (0.42) | PARP1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL983328 | 0.91 | TSHR (0.47) | PARP1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL986563 | 0.90 | TRPV1 (0.46) | PARP1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL987136 | 0.90 | PARP1 (0.42) | PARP1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4669537 | 0.81 | SMN1; SMN2 (0.50) | TSHRMEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL985355 | 0.81 | TSHR (0.58) | TSHRMEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL983212 | 0.80 | PARP1 (0.46) | PARP1TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4671224 | 0.78 | MTNR1B (0.49) | TSHRMEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL986456 | 0.77 | EDNRA (0.49) | TSHRMEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL4669565 | 0.75 | TSHR (0.53) | TSHRMEN1KMT2ASMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | claimed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | claimed |
| EP-1732898-A1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2006-12-20 | — | — | EP | claimed |
| WO-2005087743-A1 | TETRAHYDROISOQUINOLINE-AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON S.A. (CH) | 2005-09-22 | — | — | WO | claimed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | PARP1 2752/4885TSHR 42/4885MEN1 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.